About SURMOUNT-5 SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, Phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes
Becton Dickinson
Thats why its especially important to find a provider who is knowledgeable and comfortable and open in discussing these concerns. So, how can you get your libido back
Moreover, GLP-1R in EAT positively correlates with genes associated with brown adipose tissue activity, FA oxidation, and white-to-brown adipocyte differentiation, while showing a negative correlation with pro-adipogenic genes (95, 161)